Amedisys Shares Rise as UnitedHealth Looks to Upend Option Care Deal
By Colin Kellaher
Amedisys shares jumped nearly 15% on Monday after the healthcare-services provider received an unsolicited, $3.26 billion takeover proposal from UnitedHealth Group's Optum health-services arm.
Optum said it is offering $100 a share in cash for Amedisys in a bid that could scuttle a prior agreement by Option Care Health to acquire Amedisys in an all-stock transaction.
Option Care in early May said it would issue 3.0213 shares, worth $99.07 when the deal was announced, for each share of Amedisys. But shares of Option Care have fallen since then, bringing the value of the transaction to $86.29 a share at the close of trading Friday.
Optum's offer, meanwhile, represents a 26% premium to Friday's closing price of $79.47 for Amedisys and a 27% premium to the Baton Rouge, La., company's closing price of $78.63 on May 3, before the Option Care deal was announced.
Amedisys said its board determined that the Optum proposal could reasonably be expected to result in an superior deal under the terms of its agreement with Option Care, and that it has begun exploratory talks with its new suitor.
Optum said its proposal has no financing contingency, and that it is confident it can secure regulatory approval for a deal.
Option Care, for its part, said its planned union with Amedisys offers a high degree of certainty in obtaining regulatory clearance due to the complementary nature of their businesses, and that the deal would allow shareholders of both companies to participate in the upside of the combined organization.
Shares of Amedisys were recently up nearly 15% to $91.09 in early trading Monday, while shares of Option Care tacked on 7.5% to $30.69 and shares of UnitedHealth edged up 0.1% to $499.82.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 05, 2023 10:29 ET (14:29 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
What the Fed’s QT Program Is, and Why Its End Matters
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now
-
Paramount Earnings: CEO Has Gone, For-Sale Sign Is Up; Good Results Would’ve Been Nice to Learn
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?